After a year of major investments, Recipharm sells its assets in Europe – Endpoints News

Recipharm is organizing a garage sale to start the New Year.

The company announced two deals on Monday, as Swedish biotech sold its manufacturing site in Fontaine-lès-Dijon, France, to a newly created Astrea Pharma CDMO. It also sold Aesica Pharmaceuticals and the UK active pharmaceutical ingredients manufacturing site to Pharmaron.

The sale will help streamline Recipharm’s operations and improve its financial position as it attempts to position itself among the top five CDMOs, CEO Marc Funk said in a statement.

“We see this as a positive step in streamlining our operations and consolidating our position as one of the world’s top five contract development and manufacturing organizations,” he said of the agreement with Astrea. “I am happy that this business will get a committed owner with the ability and the ability to develop it to its full potential. We will continue to develop and invest in our very successful contract manufacturing business. “

Astrea Pharma is in the process of developing its manufacturing network and its offers. The company is planning further acquisitions down the line. The Cramlington site in Newcastle, UK has a commercial capacity of 1,076 square feet, approved by the MHRA and the FDA, among other regulatory agencies. This is Astrea’s first investment as the CDMO provider has just been created by a team of established industry veterans.

Meanwhile, Pharmaron is in a similar boat and looks to strengthen its already existing API manufacturing operations in Hoddesdon as it tries to offer full end-to-end services in the UK. This sale will allow the company to offer customers more customizable options.

Recipharm is rapidly expanding its production in areas of the world that need it. In July 2021, the company announced the construction of a new fill-finish plant in Uttarakhand, India, near Dehradun, as part of a partnership with the Sobti family that began in 2019.

It is also building a finishing plant in Morocco, largely thanks to a $ 500 million investment from the government over the next five years. This site will focus on manufacturing vaccines for Africa, which has fallen far behind in international immunization efforts. It will be designed to reflect the location of Monts, France, and is expected to be ready by 2023.

Sanofi sold its UK respiratory medicine manufacturing site to Recipharm in June in a $ 60 million deal. Recipharm has hired all of the plant’s 450 employees.

Editor’s Note: For more information and exclusive Pace of Manufacturing coverage, subscribe to the Endpoints Manufacturing Weekly Report in your Reader Profile.